NO20081654L - Stabiliserte GLP-1-analoger - Google Patents

Stabiliserte GLP-1-analoger

Info

Publication number
NO20081654L
NO20081654L NO20081654A NO20081654A NO20081654L NO 20081654 L NO20081654 L NO 20081654L NO 20081654 A NO20081654 A NO 20081654A NO 20081654 A NO20081654 A NO 20081654A NO 20081654 L NO20081654 L NO 20081654L
Authority
NO
Norway
Prior art keywords
amino acid
glp
analogs
base sequence
side groups
Prior art date
Application number
NO20081654A
Other languages
English (en)
Inventor
William W Bachovchin
David George Sanford
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of NO20081654L publication Critical patent/NO20081654L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

SAMMENDRAG Polypeptidanaloger tilknyttet oppfinnelsen som inkluderer a) en aminosyrebasesekvens som er minst 80 % lik en GLP-1-del og b) aminosyresidegrupper festet til C-terminus på aminosyre-basesekvensen der analogene har lenger GLP-1-lignende aktivitet enn naturlig GLP-1 og/eller der GLP-1-reseptoren har større affinitet til analogene enn naturlig GLP-1. Andre polypeptidanaloger tilknyttet oppfinnelsen inkluderer a) en aminosyre-basesekvens som er minst 50 % lik en GLP-1-del der aminosyresidegrupper i aminosyre-basesekvensen som tilsvarer P'1 -sidegrupper til GLP-1, er en aminosyreanalog med en tetrasubstituert C?-karbon og b) der aminosyresidegruppene er festet til C-terminusen på aminosyre-basesekvensen der analogene har de egenskapene som beskrives ovenfor. Oppfinnelsen inkluderer også behandlingsmetoder der disse analogene administreres. -45-
NO20081654A 2005-09-08 2008-04-03 Stabiliserte GLP-1-analoger NO20081654L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71532205P 2005-09-08 2005-09-08
PCT/US2006/034685 WO2007030519A2 (en) 2005-09-08 2006-09-07 Stabilized glp-1 analogs

Publications (1)

Publication Number Publication Date
NO20081654L true NO20081654L (no) 2008-04-03

Family

ID=37836409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081654A NO20081654L (no) 2005-09-08 2008-04-03 Stabiliserte GLP-1-analoger

Country Status (11)

Country Link
US (1) US8318668B2 (no)
EP (2) EP2497781A1 (no)
JP (1) JP2009507844A (no)
KR (1) KR20080052649A (no)
CN (1) CN101262874A (no)
AU (1) AU2006287562B2 (no)
BR (1) BRPI0615573A2 (no)
CA (1) CA2621699A1 (no)
IL (1) IL189996A0 (no)
NO (1) NO20081654L (no)
WO (1) WO2007030519A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633384B1 (en) * 2003-05-15 2012-03-14 Trustees Of Tufts College Stable analogs of glp-1
CA2726903A1 (en) * 2008-06-03 2009-12-10 Trustees Of Tufts College Long-acting glp-1 derivatives, and methods of treating cardiac dysfunction
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
ES2528496T3 (es) * 2010-05-17 2015-02-10 Betta Pharmaceuticals Co., Ltd. Nuevos análogos de péptido similar a glucagón, composición, y métodos de uso
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
EP2630965A1 (en) * 2012-02-24 2013-08-28 Curatis Pharma GmbH A polypeptide for the protection from neurodegeneration in patients with amyotrophic lateral sclerosis (ALS)
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
JP5910901B1 (ja) * 2015-03-27 2016-04-27 株式会社東洋新薬 Ｇｌｐ−１分泌促進剤
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
KR20240044545A (ko) * 2018-10-30 2024-04-04 지아닝 리우 Glp-1 수용체 작용제 활성을 갖는 glp-1 폴리펩티드 및 그의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
EP0636032A1 (en) 1992-03-25 1995-02-01 Mallinckrodt Medical, Inc. Method of intraoperatively detecting and locating tumoral tissues
RU2146128C1 (ru) 1993-01-06 2000-03-10 Кинертон Лимитед Ионный конъюгат с длительным периодом высвобождения пептида, способ синтезирования ионного конъюгата, способ синтезирования микрочастиц
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DE60228972D1 (de) * 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
CN1635900A (zh) * 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
EP1572892A4 (en) * 2001-10-18 2007-08-22 Bristol Myers Squibb Co HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1633384B1 (en) * 2003-05-15 2012-03-14 Trustees Of Tufts College Stable analogs of glp-1

Also Published As

Publication number Publication date
WO2007030519A2 (en) 2007-03-15
EP2497781A1 (en) 2012-09-12
EP1940438A4 (en) 2009-10-21
IL189996A0 (en) 2008-08-07
US8318668B2 (en) 2012-11-27
EP1940438A2 (en) 2008-07-09
US20090306338A1 (en) 2009-12-10
AU2006287562B2 (en) 2012-05-10
AU2006287562A1 (en) 2007-03-15
CN101262874A (zh) 2008-09-10
WO2007030519A3 (en) 2007-11-29
JP2009507844A (ja) 2009-02-26
BRPI0615573A2 (pt) 2011-05-24
KR20080052649A (ko) 2008-06-11
CA2621699A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
NO20081654L (no) Stabiliserte GLP-1-analoger
DK1877435T3 (da) Glucagon-lignende peptid 2 (GLP-2)-analoger
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
CY1110397T1 (el) Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης
EA200901108A1 (ru) Соагонисты глюкагоновых/glp-1-рецепторов
RU2010147076A (ru) Аналоги инсулина специфичные к изоформам
NO20061026L (no) Nye insulinderivater
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2007115837B1 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
GEP20115196B (en) Neublastin variants
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
DE602005025989D1 (de) Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden
MX2015016560A (es) Proteina analgesica aislada de la secrecion de la rana trachycephalous venulosus.
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
MX2021013702A (es) Subunidad s2 modificada de la proteina de espicula de coronavirus.
CA2722618A1 (en) Method of treating degenerative diseases
TH98389B (th) อานาลอกใหม่ของเพปไทด์ของลำไส้ที่ออกฤทธิ์กับเส้นเลือด

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application